Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
BioCryst Pharmaceuticals Stock Price (Quote) NASDAQ:BCRX
$15.46 ( 5.17% ) Monday, 25th Oct 2021
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $13.10 | $15.59 | Monday, 25th Oct 2021 BCRX stock ended at $15.46. This is 5.17% more than the trading day before Friday, 22nd Oct 2021. During the day the stock fluctuated 6.02% from a day low at $14.61 to a day high of $15.49. |
| 90 days | $13.10 | $18.48 | |
| 52 weeks | $3.57 | $18.48 |
Historical BioCryst Pharmaceuticals prices
| Date | Open | High | Low | Close | Volume |
| 2021-10-25 | $14.71 | $15.49 | $14.61 | $15.46 | 2 608 690 |
| 2021-10-22 | $14.60 | $14.77 | $14.34 | $14.70 | 1 522 581 |
| 2021-10-21 | $14.33 | $14.70 | $14.28 | $14.61 | 1 410 819 |
| 2021-10-20 | $14.97 | $15.08 | $14.31 | $14.33 | 2 405 177 |
| 2021-10-19 | $15.00 | $15.28 | $14.76 | $15.04 | 1 868 279 |
| 2021-10-18 | $15.10 | $15.24 | $14.91 | $14.92 | 3 064 200 |
| 2021-10-15 | $15.44 | $15.54 | $15.12 | $15.13 | 1 969 044 |
| 2021-10-14 | $15.13 | $15.59 | $15.13 | $15.45 | 2 689 105 |
| 2021-10-13 | $14.82 | $15.01 | $14.59 | $14.99 | 2 517 297 |
| 2021-10-12 | $14.50 | $15.00 | $14.40 | $14.71 | 2 192 097 |
| 2021-10-11 | $14.49 | $14.61 | $14.35 | $14.42 | 1 689 326 |
| 2021-10-08 | $14.01 | $14.48 | $13.72 | $14.46 | 2 343 638 |
| 2021-10-07 | $13.60 | $13.96 | $13.54 | $13.96 | 1 962 684 |
| 2021-10-06 | $13.49 | $13.69 | $13.29 | $13.53 | 2 179 961 |
| 2021-10-05 | $13.35 | $13.79 | $13.35 | $13.73 | 1 833 024 |
| 2021-10-04 | $13.51 | $13.70 | $13.10 | $13.31 | 3 177 103 |
| 2021-10-01 | $14.25 | $14.35 | $13.63 | $13.73 | 4 296 410 |
| 2021-09-30 | $14.49 | $14.74 | $14.20 | $14.37 | 3 048 186 |
| 2021-09-29 | $14.89 | $15.00 | $14.36 | $14.38 | 2 642 595 |
| 2021-09-28 | $15.30 | $15.32 | $14.70 | $14.73 | 2 661 738 |
| 2021-09-27 | $15.00 | $15.45 | $14.83 | $15.38 | 2 746 282 |
| 2021-09-24 | $15.25 | $15.30 | $14.91 | $14.92 | 2 112 388 |
| 2021-09-23 | $15.30 | $15.46 | $15.18 | $15.37 | 1 851 886 |
| 2021-09-22 | $15.47 | $15.68 | $15.35 | $15.39 | 1 628 593 |
| 2021-09-21 | $15.16 | $15.49 | $15.11 | $15.32 | 1 719 658 |
| 2021-09-20 | $15.20 | $15.54 | $14.80 | $15.02 | 2 782 620 |
| 2021-09-17 | $15.35 | $15.74 | $15.10 | $15.70 | 3 993 937 |
| 2021-09-16 | $15.01 | $15.31 | $14.90 | $15.21 | 1 351 647 |
| 2021-09-15 | $15.40 | $15.40 | $14.82 | $15.07 | 2 111 858 |
| 2021-09-14 | $15.53 | $16.12 | $15.43 | $15.48 | 2 362 207 |
| 2021-09-13 | $15.26 | $15.52 | $14.85 | $15.49 | 2 596 940 |
| 2021-09-10 | $15.25 | $15.40 | $14.86 | $15.20 | 2 495 089 |
| 2021-09-09 | $14.87 | $15.79 | $14.87 | $15.25 | 3 518 279 |
| 2021-09-08 | $15.07 | $15.09 | $14.57 | $14.96 | 2 513 076 |
| 2021-09-07 | $15.60 | $15.61 | $14.92 | $15.10 | 2 161 971 |
| 2021-09-03 | $15.84 | $15.90 | $15.35 | $15.66 | 1 500 098 |
| 2021-09-02 | $16.17 | $16.22 | $15.87 | $15.91 | 1 301 974 |
| 2021-09-01 | $15.89 | $16.20 | $15.84 | $16.15 | 1 545 418 |
| 2021-08-31 | $15.81 | $16.28 | $15.79 | $15.92 | 1 454 657 |
| 2021-08-30 | $15.65 | $15.94 | $15.46 | $15.70 | 1 418 784 |
| 2021-08-27 | $15.37 | $15.83 | $15.22 | $15.66 | 1 813 651 |
| 2021-08-26 | $15.44 | $15.71 | $15.21 | $15.34 | 1 793 259 |
| 2021-08-25 | $15.45 | $15.92 | $15.31 | $15.47 | 1 671 210 |
| 2021-08-24 | $15.21 | $15.53 | $14.92 | $15.45 | 1 782 258 |
| 2021-08-23 | $14.48 | $15.14 | $14.45 | $15.12 | 2 246 903 |
| 2021-08-20 | $14.06 | $14.57 | $14.00 | $14.21 | 2 725 224 |
| 2021-08-19 | $14.56 | $14.82 | $14.19 | $14.24 | 2 410 174 |
| 2021-08-18 | $14.40 | $15.00 | $14.16 | $14.57 | 2 741 944 |
| 2021-08-17 | $14.89 | $15.36 | $14.31 | $14.38 | 4 553 626 |
| 2021-08-16 | $16.00 | $16.00 | $15.18 | $15.27 | 2 420 260 |
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II/III clinical trial for hereditary angioedema (HAE); BCX7353, ... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 95.000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
